Cargando…

Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom

PURPOSE: Ocular mucous membrane pemphigoid (OcMMP) is a sight-threatening autoimmune disease in which referral to specialists units for further management is a common practise. This study aims to describe referral patterns, disease phenotype and management strategies in patients who present with eit...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, G P, Radford, C, Nightingale, P, Dart, J K G, Rauz, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173873/
https://www.ncbi.nlm.nih.gov/pubmed/21799523
http://dx.doi.org/10.1038/eye.2011.175
_version_ 1782212004031758336
author Williams, G P
Radford, C
Nightingale, P
Dart, J K G
Rauz, S
author_facet Williams, G P
Radford, C
Nightingale, P
Dart, J K G
Rauz, S
author_sort Williams, G P
collection PubMed
description PURPOSE: Ocular mucous membrane pemphigoid (OcMMP) is a sight-threatening autoimmune disease in which referral to specialists units for further management is a common practise. This study aims to describe referral patterns, disease phenotype and management strategies in patients who present with either early or established disease to two large tertiary care hospitals in the United Kingdom. PATIENTS AND METHODS: In all, 54 consecutive patients with a documented history of OcMMP were followed for 24 months. Two groups were defined: (i) early-onset disease (EOD:<3years, n=26, 51 eyes) and (ii) established disease (EstD:>5years, n=24, 48 eyes). Data were captured at first clinic visit, and at 12 and 24 months follow-up. Information regarding duration, activity and stage of disease, visual acuity (VA), therapeutic strategies and clinical outcome were analysed. RESULTS: Patients with EOD were younger and had more severe conjunctival inflammation (76% of inflamed eyes) than the EstD group, who had poorer VA (26.7%=VA<3/60, P<0.01) and more advanced disease. Although 40% of patients were on existing immunosuppression, 48% required initiation or switch to more potent immunotherapy. In all, 28% (14) were referred back to the originating hospitals for continued care. Although inflammation had resolved in 78% (60/77) at 12 months, persistence of inflammation and progression did not differ between the two phenotypes. Importantly, 42% demonstrated disease progression in the absence of clinically detectable inflammation. CONCLUSIONS: These data highlight that irrespective of OcMMP phenotype, initiation or escalation of potent immunosuppression is required at tertiary hospitals. Moreover, the conjunctival scarring progresses even when the eye remains clinically quiescent. Early referral to tertiary centres is recommended to optimise immunosuppression and limit long-term ocular damage.
format Online
Article
Text
id pubmed-3173873
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-31738732011-09-27 Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom Williams, G P Radford, C Nightingale, P Dart, J K G Rauz, S Eye (Lond) Clinical Study PURPOSE: Ocular mucous membrane pemphigoid (OcMMP) is a sight-threatening autoimmune disease in which referral to specialists units for further management is a common practise. This study aims to describe referral patterns, disease phenotype and management strategies in patients who present with either early or established disease to two large tertiary care hospitals in the United Kingdom. PATIENTS AND METHODS: In all, 54 consecutive patients with a documented history of OcMMP were followed for 24 months. Two groups were defined: (i) early-onset disease (EOD:<3years, n=26, 51 eyes) and (ii) established disease (EstD:>5years, n=24, 48 eyes). Data were captured at first clinic visit, and at 12 and 24 months follow-up. Information regarding duration, activity and stage of disease, visual acuity (VA), therapeutic strategies and clinical outcome were analysed. RESULTS: Patients with EOD were younger and had more severe conjunctival inflammation (76% of inflamed eyes) than the EstD group, who had poorer VA (26.7%=VA<3/60, P<0.01) and more advanced disease. Although 40% of patients were on existing immunosuppression, 48% required initiation or switch to more potent immunotherapy. In all, 28% (14) were referred back to the originating hospitals for continued care. Although inflammation had resolved in 78% (60/77) at 12 months, persistence of inflammation and progression did not differ between the two phenotypes. Importantly, 42% demonstrated disease progression in the absence of clinically detectable inflammation. CONCLUSIONS: These data highlight that irrespective of OcMMP phenotype, initiation or escalation of potent immunosuppression is required at tertiary hospitals. Moreover, the conjunctival scarring progresses even when the eye remains clinically quiescent. Early referral to tertiary centres is recommended to optimise immunosuppression and limit long-term ocular damage. Nature Publishing Group 2011-09 2011-07-29 /pmc/articles/PMC3173873/ /pubmed/21799523 http://dx.doi.org/10.1038/eye.2011.175 Text en Copyright © 2011 Royal College of Ophthalmologists http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Clinical Study
Williams, G P
Radford, C
Nightingale, P
Dart, J K G
Rauz, S
Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom
title Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom
title_full Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom
title_fullStr Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom
title_full_unstemmed Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom
title_short Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom
title_sort evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the united kingdom
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173873/
https://www.ncbi.nlm.nih.gov/pubmed/21799523
http://dx.doi.org/10.1038/eye.2011.175
work_keys_str_mv AT williamsgp evaluationofearlyandlatepresentationofpatientswithocularmucousmembranepemphigoidtotwomajortertiaryreferralhospitalsintheunitedkingdom
AT radfordc evaluationofearlyandlatepresentationofpatientswithocularmucousmembranepemphigoidtotwomajortertiaryreferralhospitalsintheunitedkingdom
AT nightingalep evaluationofearlyandlatepresentationofpatientswithocularmucousmembranepemphigoidtotwomajortertiaryreferralhospitalsintheunitedkingdom
AT dartjkg evaluationofearlyandlatepresentationofpatientswithocularmucousmembranepemphigoidtotwomajortertiaryreferralhospitalsintheunitedkingdom
AT rauzs evaluationofearlyandlatepresentationofpatientswithocularmucousmembranepemphigoidtotwomajortertiaryreferralhospitalsintheunitedkingdom